Skip to main content
PMC home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1998 May 19;158(10):1327–1330.

Unconventional therapies for cancer: 4. Hydrazine sulfate

E Kaegi
PMCID: PMC1229327  PMID: 9614826

Full Text

The Full Text of this article is available as a PDF (411.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baló J. Role of hydrazine in carcinogenesis. Adv Cancer Res. 1979;30:151–164. doi: 10.1016/s0065-230x(08)60896-9. [DOI] [PubMed] [Google Scholar]
  2. Bosan W. S., Shank R. C., MacEwen J. D., Gaworski C. L., Newberne P. M. Methylation of DNA guanine during the course of induction of liver cancer in hamsters by hydrazine or dimethylnitrosamine. Carcinogenesis. 1987 Mar;8(3):439–444. doi: 10.1093/carcin/8.3.439. [DOI] [PubMed] [Google Scholar]
  3. Bruera E. Clinical management of anorexia and cachexia in patients with advanced cancer. Oncology. 1992;49 (Suppl 2):35–42. doi: 10.1159/000227126. [DOI] [PubMed] [Google Scholar]
  4. Chlebowski R. T., Bulcavage L., Grosvenor M., Oktay E., Block J. B., Chlebowski J. S., Ali I., Elashoff R. Hydrazine sulfate influence on nutritional status and survival in non-small-cell lung cancer. J Clin Oncol. 1990 Jan;8(1):9–15. doi: 10.1200/JCO.1990.8.1.9. [DOI] [PubMed] [Google Scholar]
  5. Chlebowski R. T., Heber D. Metabolic abnormalities in cancer patients: carbohydrate metabolism. Surg Clin North Am. 1986 Oct;66(5):957–968. doi: 10.1016/s0039-6109(16)44035-1. [DOI] [PubMed] [Google Scholar]
  6. Chlebowski R. T., Heber D., Richardson B., Block J. B. Influence of hydrazine sulfate on abnormal carbohydrate metabolism in cancer patients with weight loss. Cancer Res. 1984 Feb;44(2):857–861. [PubMed] [Google Scholar]
  7. Filov V. A., Danova L. A., Gershanovich M. L., Ivin B. A., Dement'eva N. P., Breivis P. V., Ragaishene V. P., Kas'ianenko I. V., Lisitsa A. M., Mindlin S. S. Rezul'taty klinicheskogo izucheniia preparata gidrazinsul'fat. Vopr Onkol. 1990;36(6):721–726. [PubMed] [Google Scholar]
  8. Filov V. A., Gershanovich M. L., Ivin B. A., Danova L. A., Gurchin F. A., Naryshkin A. G., Leshchinskii V. I., Zemskaia A. G., Nikiforov B. M., Breivis P. V. Lechenie pervichnykh opukholei golovnogo mozga segidrinom. Vopr Onkol. 1994;40(7-12):332–336. [PubMed] [Google Scholar]
  9. Gershanovich M. L., Danova L. A., Ivin B. A., Filov V. A. Results of clinical study antitumor action of hydrazine sulfate. Nutr Cancer. 1981;3(1):7–12. doi: 10.1080/01635588109513694. [DOI] [PubMed] [Google Scholar]
  10. Gershanovich M. L., Danova L. A., Kondratyev V. B., Malyugina L. L., Stukov A. N., Seitz J. F., Filov V. A. Clinical data on the antitumor activity of hydrazine sulfate. Cancer Treat Rep. 1976 Jul;60(7):933–935. [PubMed] [Google Scholar]
  11. Gold J. Anabolic profiles in late-stage cancer patients responsive to hydrazine sulfate. Nutr Cancer. 1981;3(1):13–19. doi: 10.1080/01635588109513695. [DOI] [PubMed] [Google Scholar]
  12. Gold J. Enhancement by hydrazine sulfate of antitumor effectiveness of cytoxan, mitomycin C, methotrexate and bleomycin, in walker 256 carcinosarcoma in rats. Oncology. 1975;31(1):44–53. doi: 10.1159/000225004. [DOI] [PubMed] [Google Scholar]
  13. Gold J. Hydrazine sulfate in nonsmall-cell lung cancer. J Clin Oncol. 1990 Jun;8(6):1117–1118. doi: 10.1200/JCO.1990.8.6.1117. [DOI] [PubMed] [Google Scholar]
  14. Gold J. Hydrazine sulfate in the treatment of cancer. Cancer Treat Rep. 1976 Jul;60(7):964–965. [PubMed] [Google Scholar]
  15. Gold J. Hydrazine sulfate: a current perspective. Nutr Cancer. 1987;9(2-3):59–66. doi: 10.1080/01635588709513912. [DOI] [PubMed] [Google Scholar]
  16. Gold J. Inhibition by hydrazine sulfate and various hydrazides, of in vivo growth of Walker 256 intramuscular carcinoma, B-16 melanoma, Murphy-Sturm lymphosarcoma and L-1210 solid leukemia. Oncology. 1973;27(1):69–80. doi: 10.1159/000224721. [DOI] [PubMed] [Google Scholar]
  17. Gold J. Inhibition of Walker 256 intramuscular carcinoma in rats by administration of L-tryptophan. Oncology. 1970;24(4):291–303. doi: 10.1159/000224528. [DOI] [PubMed] [Google Scholar]
  18. Gold J. Inhibition of Walker 256 intramuscular carcinoma in rats by administration of hydrazine sulfate. Oncology. 1971;25(1):66–71. doi: 10.1159/000224555. [DOI] [PubMed] [Google Scholar]
  19. Gold J. Inhibition of gluconeogenesis at the phosphoenolpyruvate carboxykinase and pyruvate carboxylase reactions, as a means of cancer chemotherapy. Oncology. 1974;29(1):74–89. doi: 10.1159/000224889. [DOI] [PubMed] [Google Scholar]
  20. Gold J. Metabolic profiles in human solid tumors. I. A new technic for the utilization of human solid tumors in cancer research and its application to the anerobic glycolysis of isologous benign and malignant colon tissues. Cancer Res. 1966 Apr;26(4):695–705. [PubMed] [Google Scholar]
  21. Gold J. Potentiation by clofibrate of in-vivo tumor inhibition by hydrazine sulfate and cytotoxic agents, in Walker 256 carcinosarcoma. Cancer Biochem Biophys. 1978;3(1):41–45. [PubMed] [Google Scholar]
  22. Gold J. Proposed treatment of cancer by inhibition of gluconeogenesis. Oncology. 1968;22(2):185–207. doi: 10.1159/000224450. [DOI] [PubMed] [Google Scholar]
  23. Gold J. Use of hydrazine sulfate in terminal and preterminal cancer patients: results of investigational new drug (IND) study in 84 evaluable patients. Oncology. 1975;32(1):1–10. doi: 10.1159/000225043. [DOI] [PubMed] [Google Scholar]
  24. Grubbs B., Rogers W., Cameron I. Total parenteral nutrition and inhibition of gluconeogenesis on tumor-host responses. Oncology. 1979;36(5):216–223. doi: 10.1159/000225345. [DOI] [PubMed] [Google Scholar]
  25. Herbert V. Three stakes in hydrazine sulfate's heart, but questionable cancer remedies, like vampires, always rise again. J Clin Oncol. 1994 Jun;12(6):1107–1108. doi: 10.1200/JCO.1994.12.6.1107. [DOI] [PubMed] [Google Scholar]
  26. Kosty M. P., Fleishman S. B., Herndon J. E., 2nd, Coughlin K., Kornblith A. B., Scalzo A., Morris J. C., Mortimer J., Green M. R. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol. 1994 Jun;12(6):1113–1120. doi: 10.1200/JCO.1994.12.6.1113. [DOI] [PubMed] [Google Scholar]
  27. Kosty M. P., Herndon J. E., 2nd, Green M. R., McIntyre O. R. Placebo-controlled randomized study of hydrazine sulfate in lung cancer. J Clin Oncol. 1995 Jun;13(6):1529–1530. doi: 10.1200/JCO.1995.13.6.1529. [DOI] [PubMed] [Google Scholar]
  28. Lerner H. J., Regelson W. Clinical trial of hydrazine sulfate in solid tumors. Cancer Treat Rep. 1976 Jul;60(7):959–960. [PubMed] [Google Scholar]
  29. Loprinzi C. L., Goldberg R. M., Su J. Q., Mailliard J. A., Kuross S. A., Maksymiuk A. W., Kugler J. W., Jett J. R., Ghosh C., Pfeifle D. M. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol. 1994 Jun;12(6):1126–1129. doi: 10.1200/JCO.1994.12.6.1126. [DOI] [PubMed] [Google Scholar]
  30. Loprinzi C. L., Kuross S. A., O'Fallon J. R., Gesme D. H., Jr, Gerstner J. B., Rospond R. M., Cobau C. D., Goldberg R. M. Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol. 1994 Jun;12(6):1121–1125. doi: 10.1200/JCO.1994.12.6.1121. [DOI] [PubMed] [Google Scholar]
  31. MACBETH R. A., BEKESI J. G. Oxygen consumption and anaerobic glycolysis of human malignant and normal tissue. Cancer Res. 1962 Feb;22:244–248. [PubMed] [Google Scholar]
  32. Menon M. M., Bhide S. V. Perinatal carcinogenicity of isoniazid (INH) in Swiss mice. J Cancer Res Clin Oncol. 1983;105(3):258–261. doi: 10.1007/BF00395754. [DOI] [PubMed] [Google Scholar]
  33. Nelson J. A., Falk R. E. The efficacy of phloridzin and phloretin on tumor cell growth. Anticancer Res. 1993 Nov-Dec;13(6A):2287–2292. [PubMed] [Google Scholar]
  34. Noda A., Sendo T., Ohno K., Noda H., Goto S. Metabolism and cytotoxicity of hydrazine in isolated rat hepatocytes. Chem Pharm Bull (Tokyo) 1987 Jun;35(6):2538–2544. doi: 10.1248/cpb.35.2538. [DOI] [PubMed] [Google Scholar]
  35. Ochoa M., Jr, Wittes R. E., Krakoff I. H. Trial of hydrazine sulfate (NSC-150014) in patients with cancer. Cancer Chemother Rep. 1975 Nov-Dec;59(6):1151–1154. [PubMed] [Google Scholar]
  36. Ottery F. D. Supportive nutrition to prevent cachexia and improve quality of life. Semin Oncol. 1995 Apr;22(2 Suppl 3):98–111. [PubMed] [Google Scholar]
  37. Parnes H. L., Aisner J. Protein calorie malnutrition and cancer therapy. Drug Saf. 1992 Nov-Dec;7(6):404–416. doi: 10.2165/00002018-199207060-00003. [DOI] [PubMed] [Google Scholar]
  38. Piantadosi S. Hazards of small clinical trials. J Clin Oncol. 1990 Jan;8(1):1–3. doi: 10.1200/JCO.1990.8.1.1. [DOI] [PubMed] [Google Scholar]
  39. Pisters P. W., Pearlstone D. B. Protein and amino acid metabolism in cancer cachexia: investigative techniques and therapeutic interventions. Crit Rev Clin Lab Sci. 1993;30(3):223–272. doi: 10.3109/10408369309084669. [DOI] [PubMed] [Google Scholar]
  40. Ray P. D., Foster D. O., Lardy H. A. Paths of carbon in gluconeogenesis and lipogenesis. IV. Inhibition by L-tryptophan of hepatic gluconeogenesis at the level of phosphoenolpyruvate formation. J Biol Chem. 1966 Sep 10;241(17):3904–3908. [PubMed] [Google Scholar]
  41. Ray P. D., Hanson R. L., Lardy H. A. Inhibition by hydrazine of gluconeogenesis in the rat. J Biol Chem. 1970 Feb 25;245(4):690–696. [PubMed] [Google Scholar]
  42. Silverstein R., Christoffersen C. A., Morrison D. C. Modulation of endotoxin lethality in mice by hydrazine sulfate. Infect Immun. 1989 Jul;57(7):2072–2078. doi: 10.1128/iai.57.7.2072-2078.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Suzuki H., Tominaga T., Mizuno H., Kouno M., Suzuki M., Kato Y., Sato A., Okabe K., Uchikoshi T., Maezono K. Ethanol and hydrazine sulfate induced chronic hepatic injury in rats: the curative effect of administration of glucogenic amino acids. Alcohol Alcohol Suppl. 1993;1A:111–117. doi: 10.1093/alcalc/28.supplement_1a.111. [DOI] [PubMed] [Google Scholar]
  44. Tayek J. A., Heber D., Chlebowski R. T. Effect of hydrazine sulphate on whole-body protein breakdown measured by 14C-lysine metabolism in lung cancer patients. Lancet. 1987 Aug 1;2(8553):241–244. doi: 10.1016/s0140-6736(87)90828-2. [DOI] [PubMed] [Google Scholar]
  45. Toth B. Hydrazine, methylhydrazine and methylhydrazine sulfate carcinogenesis in Swiss mice. Failure of ammonium hydroxide to interfere in the development of tumors. Int J Cancer. 1972 Jan 15;9(1):109–118. doi: 10.1002/ijc.2910090113. [DOI] [PubMed] [Google Scholar]
  46. Toth B. Teratogenic hydrazines: a review. In Vivo. 1993 Jan-Feb;7(1):101–110. [PubMed] [Google Scholar]
  47. Tweedie D. J., Erikson J. M., Prough R. A. Metabolism of hydrazine anti-cancer agents. Pharmacol Ther. 1987;34(1):111–127. doi: 10.1016/0163-7258(87)90095-7. [DOI] [PubMed] [Google Scholar]
  48. WARBURG O. On the origin of cancer cells. Science. 1956 Feb 24;123(3191):309–314. doi: 10.1126/science.123.3191.309. [DOI] [PubMed] [Google Scholar]
  49. Zimmerman H. J., Ishak K. G. The hepatic injury of monoamine oxidase inhibitors. J Clin Psychopharmacol. 1987 Aug;7(4):211–213. [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES